Latebreakers: New kidney cancer guide from NCCN

The National Comprehensive Cancer Network (NCCN) has released an update to its kidney cancer guidelines. One notable change is the addition of temsirolimus (Torisel, Wyeth) as a first-line treatment option for patients with relapsed or unresectable stage IV renal cancer with both predominant clear cell and non-clear cell histology. In addition, the panel added bevacizumab (Avastin, Genentech) in combination with interferon alfa-2a as a first-line treatment for patients with relapsed or unresectable stage IV disease with predominant clear cell histology. The new guideline can be accessed at http://www.nccn.org/.